Naloxegol CV Safety Findings “Reassuring” – NEJM Study
This article was originally published in The Pink Sheet Daily
AstraZeneca’s peripherally acting mu-opioid receptor antagonist was not associated with an increased incidence of major cardiovascular events in Phase III studies of chronic pain patients with opioid-induced constipation. An FDA advisory committee will review CV safety data for the drug class June 11-12.
You may also be interested in...
Targiniq Review Shows How High FDA’s CV Safety Bar Is For Opioid Antagonists
FDA appreciated Purdue’s “Herculean” attempt to demonstrate the cardiovascular safety of its abuse-deterrent Targiniq ER, but the agency emphasized that studies must include more chronically-treated patients and should not exclude patients with a history of cardiovascular disease.
CV “Think Tank” Consensus Should Guide Safety Trials, Firms Tell FDA
Opioid-induced constipation drugs are best handled by the alternative approaches to cardiovascular safety data collection favored by public/private group of experts, sponsors argue.
AstraZeneca’s Movantik Looks Clear After FDA Panel; Salix’ Relistor Looks Cloudy
Naloxegol development program included long-term controlled trial, the advisory committee’s preferred approach for studying CV events with peripherally active mu opioid receptor antagonists for opioid-induced constipation, while methylnaltrexone may suffer from the lack of control arm in its long-term study.